Microvascular endothelial cells cultured in three-dimensional hydrogel scaffolds form a network of microvessel structures when implanted subcutaneously in mice, inosculate with host vessels, and over time remodel into large ectatic vascular structures resembling hemangiomas. When compared with infantile hemangiomas, similarities were noted, including a temporal progression from a morphological appearance of a proliferative phase to the appearance of an involuted phase, mimicking the proliferative and involutional phases of infantile hemangioma. Consistent with the progression of a proliferative phase to an involuted phase, both the murine implants and human biopsy tissue exhibit reduced expression of Ajuba, YAP, and Survivin labeling as they progressed over time. Significant numbers of CD45+, CD11b+, Mac3+ mononuclear cells were found at the 2-week time point in our implant model that correlated with the presence of CD45+, CD68+ mononuclear cells observed in biopsies of human proliferative-phase hemangiomas. At the 4-week time point in our implant model, only small numbers of CD45+ cells were detected, which again correlated with our findings of significantly diminished CD45+, CD68+ mononuclear cells in human involutional-phase hemangiomas. The demonstration of mononuclear cell infiltration transiently in the proliferative phase of these lesions suggests that the vascular proliferation and/or regression may be driven in part by an immune response. Gross and microscopic morphological appearances of human proliferative and involutional hemangiomas and our implant model correlate well with each other as do the expression levels of Hippo pathway components (Ajuba and YAP) and Survivin and correlate with proliferation in these entities. Inhibitors of Survivin and Ajuba (which we have demonstrated to inhibit proliferation and increase apoptosis in murine hemangioendothelioma cell tissue culture) may have potential as other beneficial treatments for proliferating infantile hemangiomas. This implant model may have potential as a modest through-put screen for testing and development of therapeutics targeted at the proliferative phase of infantile hemangiomas, reducing the subsequent postinvolutional scarring or deformities sometimes associated with these lesions.
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Microvascular endothelial cells cultured in three-dimensional hydrogel scaffolds form a network of microvessel structures when implanted subcutaneously in mice, inosculate with host vessels, and over time remodel into large ectatic vascular structures resembling hemangiomas. When compared with infantile hemangiomas, similarities were noted, including a temporal progression from a morphological appearance of a proliferative phase to the appearance of an involuted phase, mimicking the proliferative and involutional phases of infantile hemangioma. Consistent with the progression of a proliferative phase to an involuted phase, both the murine implants and human biopsy tissue exhibit reduced expression of Ajuba, YAP, and Survivin labeling as they progressed over time. Significant numbers of CD45+, CD11b+, Mac3+ mononuclear cells were found at the 2-week time point in our implant model that correlated with the presence of CD45+, CD68+ mononuclear cells observed in biopsies of human proliferative-phase hemangiomas. At the 4-week time point in our implant model, only small numbers of CD45+ cells were detected, which again correlated with our findings of significantly diminished CD45+, CD68+ mononuclear cells in human involutional-phase hemangiomas. The demonstration of mononuclear cell infiltration transiently in the proliferative phase of these lesions suggests that the vascular proliferation and/or regression may be driven in part by an immune response. Gross and microscopic morphological appearances of human proliferative and involutional hemangiomas and our implant model correlate well with each other as do the expression levels of Hippo pathway components (Ajuba and YAP) and Survivin and correlate with proliferation in these entities. Inhibitors of Survivin and Ajuba (which we have demonstrated to inhibit proliferation and increase apoptosis in murine hemangioendothelioma cell tissue culture) may have potential as other beneficial treatments for proliferating infantile hemangiomas. This implant model may have potential as a modest through-put screen for testing and development of therapeutics targeted at the proliferative phase of infantile hemangiomas, reducing the subsequent postinvolutional scarring or deformities sometimes associated with these lesions. Implantation of a variety of cell types in three-dimensional scaffolds (biological and synthetic biocompatible) has been used extensively in a wide range of settings, including attempts to improve structure and function of mesenchymal scaffolds in a variety of soft and hard tissue applications, 1,2 enhancement of vasculature following injury, 3 enhancing repair/recovery of parenchymal tissue following injury, 4 and production and delivery of soluble proteins. 5 In addition, implantation of cells in three-dimensional scaffolds has been used to enhance survivability 6 and investigate basic physiological and pathophysiological processes, including angiogenesis, 7, 8 cell migration and invasion, 9 differentiation, 10 and neoplasia. 11 Using both biological (collagen and other ECM components) and biocompatible (hydrogels) scaffolds we have demonstrated the efficacy of employing scaffolds in combination with selected cell types as protein delivery vehicles 5 as well as in several angiogenesis and neural progenitor studies. 10, 12, 13 In this report, we found that when implanted subcutaneously, immortalized murine microvascular endothelial cells dispersed in a hydrogel scaffold undergo marked proliferation and became vascularized. Interestingly, over time (4 weeks) these implants developed a lumpy, bulging appearance, resembling clusters of dilated vessels. These morphological changes that have occurred over time resemble the morphological changes observed in infantile hemangiomas as they progress from the proliferative to the involutional phase. In this report, we also have documented the dynamic presence of immune cells and the expression of selected proteins known to modulate proliferation and survival in a wide range of cell types, including endothelia in both the implants and infantile hemangiomas. Specifically, we illustrate the changes in macrophage presence and expression of Ajuba, Survivin, and YAP in both the clinical material and the murine implants and suggest that the murine implants may serve as a useful animal model of this entity, facilitating the development of therapeutics focused on blunting the proliferative phase and reducing the postinvolutional scarring that sometimes accompanies the regression of these lesions.
MATERIALS AND METHODS
Cell Culture Murine brain endothelial cells (BECs) were isolated from cerebral microvessels of C57BL/6 wild-type mice (WT-BEC) (The Jackson Laboratory, Bar Harbor, ME, USA) as shown previously. [14] [15] [16] WT-BEC was cultured on 1.5% gelatin (Cat. No. G8-500, Thermo Fisher Scientific, Waltham, MA, USA) coated plates in BEC media (Dulbecco's Modified Eagle's Medium (DMEM) with High Glucose (Life Technologies, Grand Island, NY, USA) containing 10% FBS, 2 mM L-glutamine, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 10 mM HEPES (pH 7.4), 10 − 5 M β-mercaptoethanol, 100 U/ml penicillin, and 100 μg/ml streptomycin (Life Technologies)) in 8% CO 2 at 37°C. 9, 16 Cells were used in passage 22 and cultured under normoxic (20% O 2 ) condition.
Dispersing Endothelial Cells in Poly(Ethylene Glycol)/ Poly(L-Lysine) (PEG/PLL) Hydrogels We performed testing for endotoxin on the polymer precursors and have not observed indications consistent with endotoxin contamination. The inflammation we observed appears to be related to the cell types used. When these same materials are used with other cell types, we do not see similar infiltration of inflammatory cells subcutaneously and in the spinal cord. 3, 10, 12, 17, 18 Irgacure 2959 initiator was dissolved in BEC media at a concentration of 5 mg/ml and filtered with 0.22-μm sterile syringe filter (Cat. No. SLGP033RS, Millex-GP Syringe Filter Unit, 0.22-μm pore size hydrophilic polyethersulfone membrane; Merck Millipore, Billerica, MA, USA) before crosslinking. PEG/PLL macromers 10, [17] [18] [19] were dissolved at a concentration of 10% (w/v) in the Irgacure 2959 initiator solution and mixed with WT-BEC at a concentration of 2.5 × 10 6 cells/ml. Aliquots of endothelial cells mixed with the macromer solution was placed under UV light for 10 min at 6 mW/cm 2 , which elicited formation of the gels with endothelial cells dispersed throughout.
Surgical Procedures
Ten 12-week-old C57 black mice (C57BL/6) (The Jackson Laboratory) were used for the subcutaneous implantation studies. Each mouse was anesthetized with an intra-peritoneal injection of ketamine (100 mg/kg) and xylazine (20 mg/kg). An incision of 10 mm in length was made through the skin overlying the thoracic spine, and subcutaneous pockets were created bilaterally by blunt dissection under the skin. A round hydrogel disk (5 mm diameter) was implanted in each mouse, one in each pocket. The incision was closed with surgical clips, and the mice were maintained on a heating pad until they regained mobility. Following euthanasia, five Hydrogel implants were retrieved at 2 and 4 weeks, respectively, after implantation and fixed in 5% paraformaldehyde in 50 mM HEPES buffer (pH 7. 
Antibodies
Antibodies were directed against mouse CD31 (PECAM-1) (affinity purified SL-4), raised in rabbit and purified as described elsewhere. 20 
Clinical Cases
Representative proliferating-and involuting-phase cutaneous infantile hemangioma cases were collected for the present study from the Surgical Pathology files of the Yale University School of Medicine. The surgical samples were fixed in 10% formalin, processed routinely, and embedded in paraffin. Serial sections cut at 5 μm from paraffin blocks were used for H&E staining and immunohistochemistry. Briefly, a retrospective search of the pathology database was performed to identify cases of vascular tumors with the diagnosis of hemangioma. Over a 10-year period, a total of 58 cases were retrieved with the diagnosis. The original H&E slides were reviewed in a blinded manner by three pathologists (one pathologist was aware of the diagnosis on record) to determine whether there was concordance between the archived diagnosis and the diagnosis by the pathologists involved in this study. Out of these 58 cases, 13 cases were selected by consensus review, comprised of 6 infantile hemangiomas in the proliferative phase and 7 in the involutional phase. The selection was also partially based on the presence of sufficient tissue to perform additional immunohistochemical and microarray studies. Following immunohistochemical staining, the slides were reviewed in a blinded manner from the original diagnosis by all the pathologists. Additional details regarding the cases are shown in Table 1 . The study was approved by the institution's IRB (Institutional Review Board).
Tissue Microarray
Thirteen representative proliferating-and involuting-phase infantile hemangiomas were collected from the Surgical Pathology files of the Yale University School of Medicine. All cases were reviewed using clinical records and conventional H&E staining slides before selecting typical doubleredundant histopathological areas (6 mm diameters, each) for the tissue microarray. Paraffin-embedded tissue microarray slides were generated by the Yale University Pathology Department Tissue Services (YPTS) and used for immunohistochemistry. At the 4-week time point, immuno-co-localization with CD31 ( Figure 5 , left column) and VE-cadherin (first row) illustrates their co-localization in endothelial cells lining the ectatic blood-filled spaces. Immuno-co-localization with CD31 and Ki67 (second row) revealed Ki67 positivity in two endothelial lining cells (arrows). Survivin expression (third row) was not detected at this time point (third row). Robust YAP expression appeared limited to the lining endothelial cells (inset) but absent in the dense connective tissue septa. Modest phospho-YAP expression (fifth row) also appeared limited to the lining endothelial cells (inset) but absent in the dense connective tissue septa. At the 4-week time point, immuno-co-localization of CD31 and GLUT-1 (sixth row) appears in a patchy, irregular pattern restricted to 
Survivin and Hippo Pathway Component Expression in Proliferative and Involuting Infantile Hemangioma Mirrors Expression Levels in Hydrogel-Endothelial Cell Implants
Histological and immunohistochemical analyses of proliferative-phase infantile hemangiomas revealed similarities to the hydrogel-endothelial cell 2-week implants in their CD31, GLUT-1, Ajuba, Survivin, YAP, and CD45 expression levels ( Figure 6 ). Low-power (left panel) and high-power (second panel) H&E-stained sections revealed solid regions consisting of small vascular lumina lined by flattened endothelial cells among clusters of mononuclear cells in a scant stroma (lower half of the image), illustrative of the proliferative phase (Figures 6a 1-3 ) . Labeling with anti-CD31 revealed robust staining of endothelial cells lining the lumina and single endothelial cells present throughout the lower half of the image and predominately endothelial cell lining cells in the upper half of the image (left two panels, second row, lower half of the image, and the inset; Figures 6a 3-6 ). As observed for CD31 staining, GLUT-1 exhibited robust staining of endothelial cells lining the lumina and occasional single endothelial cells present throughout the image and the inset, predominately endothelial cell lining cells in the upper half of the image (left two panels, third row, and the inset; Figures 6a [6] [7] [8] [9] ). Labeling with anti-Ajuba revealed predominately nuclear and modest cytoplasmic staining of endothelial lining cells and single endothelial cells throughout the entire section (Figures 6a 10-12 ). Labeling with anti-Survivin also revealed predominately nuclear staining of endothelial lining cells and single endothelial cells throughout the entire section (Figures 6a 13-15 ). YAP staining was also found to be present in both the nuclei and cytoplasm of the luminal lining endothelial cells and occasional single cells in between the lumina (Figures 6a 16-18 ). CD45 staining revealed robust staining of many mononuclear cells present throughout the more solid areas of the proliferative hemangioma ( Figures  6a 19-21 ). To support our hypothesis that the CD45-positive cells were macrophages, we stained representative infantile hemangioma lesions with anti-CD68. Examination of the stained tissue revealed significant numbers of CD68-positive cells interspersed among endothelial cells and the formed vessel segments in lesional tissue (Figures 6a 22-24 ) . CD3 staining revealed a very small number of CD3-positive cells interspersed the endothelial cells and vessel segments of lesional tissue (Figures 6a 25-27 ). As expected, staining the hemangioma specimens with Ki67 revealed robust nuclear staining in the proliferative specimens (Figures 6a 28-30 ).
Histological and immunohistochemical analyses of the involuted-phase infantile hemangiomas revealed similarities to the hydrogel-endothelial cell 4-week implants in their 
Hippo and survivin in infantile hemangioma
M Tsuneki et al CD31, Survivin, YAP, CD45, and GLUT-1 expression levels. Low-power and high-power H&E-stained sections revealed various sized vascular lumina lined by flattened endothelial cells interspersed in a dense fibrous stroma having an occasional cell interspersed throughout the stroma. (Figures  6b 1-3 ) , illustrative of the involuted phase. Labeling with anti-CD31 again revealed robust staining of endothelial cells lining the lumina and rare single endothelial cells interspersed throughout the stroma (Figures 6b 4-6 ). Labeling with anti-GLUT-1 exhibited moderate staining of endothelial cells lining the lumina (Figures 6b 7-9 ). Labeling with anti-Ajuba revealed very modest cytoplasmic staining of endothelial lining cells (Figures 6b 10-12 ). Labeling with anti-Survivin was not detectable (Figures 6b 13-15 ), as was YAP staining (Figures 6b [16] [17] [18] ). CD45 staining in involuted hemangiomas exhibit moderate staining of only a few mononuclear cells in the connective tissue stroma and occasional positive cells in the lumina of vessels in the tumor (Figures 6b 19-21 ) . Examination of the stained tissue also revealed rare CD68-positive cells interspersed among endothelial cells and formed vessel segments in lesional tissue (Figures 6b 22-24 ). CD3 staining also revealed rare CD3-positive cells interspersed among the vessel segments of lesional tissue (Figures 6b [24] [25] [26] [27] ). In contrast to the proliferative specimens, staining of the involutional Figure 5 Dynamic Survivin and Hippo pathway component expression in the peri-implant and implant areas at the 4-week time point. In contrast to the 2-week time point, hydrogel implants after 4 weeks exhibited differential localizations and expression levels of VE-cadherin, Ki67, Survivin, Hippo pathway components (YAP and phosphor-YAP), and GLUT-1. Immunofluorescence staining for CD31 (red, left column), VE-cadherin (VEC) (green, middle column, top row), merged CD31/VEC/DAPI (right column, top row), Ki67 (green, middle column, second row), merged CD31/Ki67/DAPI (right column, second row), Survivin (green, middle column, third row), merged CD31/Survivin/DAPI (right column, third row), YAP (green, middle column, fourth row), merged CD31/YAP/DAPI (right column, fourth row), phospho-YAP (P-YAP) (green, middle column, fifth row), merged CD31/P-YAP/DAPI (right column, fifth row), GLUT-1 (green, middle column, bottom row), and merged CD31/GLUT-1/DAPI (right column, bottom row and inset) revealed modest staining of Ki67 (arrows) and Survivin, robust YAP, and moderate P-YAP staining in endothelial cells. In contrast to the 2-week implants, the 4-week implant connective tissues exhibited very modest CD31, VE-cadherin Survivin, YAP, and P-YAP staining. Interestingly. GLUT-1 was localized to the microvasculature in the connective tissue septa, colocalizing with CD31 but was absent from the endothelia lining the ectatic blood-filled spaces (left column, bottom row, and inset). Scale bars, 50 μm.
Hippo and survivin in infantile hemangioma M Tsuneki et al hemangioma specimens with Ki67 revealed very modest nuclear staining (Figures 6b 28-30 ).
Expression Levels of Ajuba (and to a Lesser Extent YAP, Survivin, and CD45) in Infantile Hemangioma Correlate With the Proliferative and Involuting Phases of Samples Contained in our Tissue Microarray Immunohistological analyses of representative proliferativeand involuting-phase infantile hemangiomas from our 6-mm double redundant tissue microarray using anti-Ajuba, -Survivin, -YAP, and -CD45 reagents revealed that in the proliferative phase Ki67, Ajuba, Survivin, YAP, and CD45 expression was greater than that observed in the involuted phase of infantile hemangiomas (data not shown). This prompted analyses of the 13 proliferative-and involuting-phase infantile hemangiomas included in our tissue microarray, using anti-Ki67 (not shown), -Ajuba, -YAP, -Survivin and -CD45 reagents. This staining revealed that the staining intensities noted in the proliferative and involuted phases of infantile hemangiomas was observed as a continuum, with Ajuba intensity correlating with the degree of proliferative histology ( Figure 7 , first and fifth columns), with cases 1-7 correlating with a proliferative phenotype. Cases 8 and 9 displayed an intermediate staining pattern consistent with lesions in transition from proliferative to involuting phase and cases 10-13 displayed staining patterns consistent with involuting-phase hemangiomas. Although exhibiting similar expression ranges (albeit at less intense levels compared with Ajuba staining), YAP (second and sixth columns), Survivin (third and seventh columns), and CD45 (fourth and eighth columns) expression levels were also demonstrative of a continuum of staining of infantile hemangiomas from proliferative (more intense) to involuting (decreased intensity) phases.
Upon comparing our immunohistochemical-and morphological-based diagnoses (Figure 7 ) with the H&E diagnoses ( Table 1 , H&E diagnosis), we found agreement with all but two cases (3 and 7) in which our immunochemical data placed them in the proliferative phase (Table 1 , Surv/ Hippo analysis). Additionally, our analysis placed cases 8 and 9 in a transitional phase, expressing areas consistent with both proliferative and involutional phases. . Proliferative lesions exhibited intense nuclear and cytoplasmic labeling with anti-Ajuba (a [10] [11] [12] ) and robust nuclear labeling with anti-Survivin (a [13] [14] [15] ) and YAP (A [16] [17] [18] ). In addition, the proliferative lesions exhibited labeling with anti-CD45 and -CD68, consistent with macrophages (a [19] [20] [21] [22] [23] [24] ). Additionally, these lesions exhibited occasional labeling with anti-CD3, indicative of T lymphocytes (a [25] [26] [27] ). Proliferative lesions exhibited intense nuclear and labeling with anti-Ki67 (a [28] [29] [30] ). Scale bars: a 1, 4, 7, 10, 13, 16, 19, 22, 25, 28 = 100 μm; a 2, 5, 8, 11, 14, 17, 20, 23, 26, 29 = 50 μm; a 3, 6, 9, 12, 15, 18, 22, 24, 27, 30 . In contrast to the proliferative lesions, the involutional lesions exhibited very modest to undetectable labeling with anti-Ajuba (b [10] [11] [12] ), Survivin (b [13] [14] [15] , and YAP (b [16] [17] [18] ). Similarly, anti-CD45, -CD68, and -CD3 labeling labeled rare cells in the involutional lesions (b [19] [20] [21] [22] [23] [24] [25] [26] [27] ). In contrast to the proliferative lesions, the involutional lesions exhibited modest nuclear labeling with anti-Ki67 (B [28] [29] [30] 
DISCUSSION
Infantile hemangiomas are common benign tumors in childhood, being diagnosed in as many as 10% of children aged o1 year, with increased incidence in premature infants and females. [21] [22] [23] Hemangiomas share a common feature of robust proliferation at the initial stages during their development followed by a regressive phase and scar formation. 22 The majority of these lesions do not require any intervention. However, facial lesions and lesions of large size sometimes do require treatment that has included systemic steroids, immune regulators, Interferon alpha, propranolol, radiation, laser treatment, and surgery, 22, [24] [25] [26] [27] all having some potential side effects. Several underlying mechanisms involved in the development of infantile hemangiomas have been proposed and discussed, although a definitive mechanism is still elusive. 23, 26, [28] [29] [30] [31] Evidence has been accrued suggesting that the placenta may be related to infantile hemangioma in that these lesions have been associated with mothers who have undergone chorionic villus sampling. Although interesting, investigators have not observed maternal-fetal chimerism and that the genotype of the lesions is that of the child, not the mother. Another theory also involving the placenta is based on the observations that tumor-derived secreted substances can elicit changes in specific organs and tissues that predispose them to metastases 32, 33 (in this case, the fetal placenta or a chorangioma would be the tissue source of the putative substances and the hemangioma precursor cells). In addition, the cell of origin of hemangiomas has been postulated to be the result of a mutation(s) in a precursor cell as investigators have determined that cells isolated from hemangioma tissue have exhibited clonality. 23, 34 Additionally, local and systemic perturbations in the individual during infancy may predispose to the development of hemangiomas. 35 Specifically, hypoxia has been suggested as a driver leading to upregulation of transcription factors and chemokines, which can elicit recruitment of endothelial progenitor cells and hemangioma development. 35 Although contributing to our understanding of hemangiomas, no single theory adequately explains all pathobiology of these lesions and highlights the complexity of these lesions. 27, 30, 31 Our findings that the kinetics of our three-dimensional subcutaneous implanted hydrogel-endothelial cell cultures mimicked the proliferative and involutional phases of human infantile hemangiomas prompted us to further characterize and compare the cellular composition of our murine model and the human counterpart. Surprisingly, we noted that many of the cells comprising the murine implants at the 2-week time point were not endothelial but expressed the markers of mononuclear cells, namely CD45, CD11b, and Mac3. The inflammation we observed appears to be related to the cell types used. When these same materials are used with other cell types, we do not see a similar infiltration of inflammatory cells. 3, 10, 12, 17, 18 Analysis of the proliferative-phase human infantile hemangiomas also revealed the presence of CD45-and CD68-positive cells interspersed among single and lumen-forming endothelia. When the murine implants were assessed for the presence of CD45, CD11b, and Mac3 at the 4-week time point, a significantly reduced number of these cells were noted. Similarly, analysis of the involutional-phase human infantile hemangiomas revealed a significantly reduced presence of CD45-and CD68-positive cells interspersed among lumen-forming endothelia. These similarities between the kinetics of our murine subcutaneous implants and the human biopsies suggests a possible dynamic, temporal role for immune cells in the proliferative phase of infantile hemangiomas, either as an initiating cell in the proliferative phase and/or as a cell involved in downregulating the proliferative response or inhibiting proliferative signals following an initiating event. Precedence for such a role for monocytes/macrophages has been well documented during the inflammatory process 36, 37 as well as during developmental/regenerative processes 36, 38, 39 and has been observed and documented in infantile hemangiomas. 27, 40, 41 Our finding of the increased numbers of CD45+, CD58+ cells in proliferating infantile hemangiomas compared with involuting infantile hemangiomas provides additional evidence suggesting the potential importance of these cells and their interactions with endothelial cells in the biological behavior of this entity. Additionally, this observation adds another potential mechanism explaining, in part, yet another aspect of local and/or systemic perturbations in the individual during infancy (which may evoke an immune response) and thus may predispose to the development of hemangiomas and/or their involution. The presence of specific myeloid cells has been postulated as having roles in the proliferative phase and involution noted in the life cycle of infantile hemangiomas. 27, 41 It has been reported that treatment with an immune regulator, imiquimod cream, caused accelerated regression of proliferative hemangiomas, 27 consistent with a role of immune cells in the modulation of the proliferative phase of these lesions. Regarding modulation of the involutional phase and subsequent scarring or fibrosis of infantile hemangiomas, other than the association of involution with age there has been no mechanism demonstrated. 42 In addition, in light of our recent findings demonstrating a role for Survivin and Hippo pathway components as modulators of endothelial and hemangioendothelioma proliferation and apoptosis in vitro, 9,14 we embarked upon an assessment of components of these pathways in our murine model and in patient samples of infantile hemangioma. Interestingly, we found early (2 week) implants and proliferating infantile hemangiomas exhibited more robust Survivin, YAP, and Ajuba staining than late (4 week) implants and involutional infantile hemangiomas. Of these molecules, Ajuba (an inhibitor of LATS/12, a kinase that phosphorylates YAP, targeting it to the proteosome, reducing Hippo activity, and eliciting increased proliferation and reduced apoptosis 9, 14 ) , gave the best correlation with the phase of the hemangiomas. Interestingly, Survivin has been examined in canine vascular tumors 43 and found not to be increased in hemangiomas.
However, the data shown in this report 43 are illustrative of an involutional-phase hemangioma, which is consistent with our results. Overall, our data are consistent with the possibility that the Survivin and Hippo pathways are modulators of proliferation and apoptosis in both the murine and human entities and that inhibition of either or both of these pathways (inhibition of Survivin activity and/or neutralization of Hippo pathway inhibitors) may be potential therapeutic targets. 44 As we have recently noted, a small-molecule Survivin inhibitor YM155, exhibiting modest side effects and currently under study in clinical trials for solid tumors, is an effective modulator of murine hemangioendothelioma (EOMA) cells in culture while having no appreciable effect on wild-type endothelial cells in vitro. 9 This small molecule inhibits Survivin expression by interfering with Sp1 binding to the Survivin promoter. 45 Inhibiting Survivin expression was found to induce the expression of VE-cadherin and CD31, facilitating adherens junction formation, thus enhancing contact inhibition-mediated reduction of proliferation, inhibiting Ajuba expression, resulting in activation of the Hippo pathway, reducing nuclear YAP levels, reducing proliferation, and increasing apoptosis. 9 Thus we speculate that selective inhibition of Survivin and/or inhibitors of the Hippo pathway may have potential as another beneficial treatment for proliferating infantile hemangiomas that have significant pathological potential, reducing subsequent scar formation and disfigurement as well as for other more aggressive vascular tumors. Finally, our murine model may have potential as a model that will allow for the elucidation of the underlying mechanisms driving the proliferative and involutional phases of this entity and as a modest through-put screen for compounds targeting these and other signaling pathways, leading to human phase trials.
